FDA clears Aethlon's Hemopurifier IDE supplement to include Ebola
Dec 31 2014, 07:23 ET | About: Aethlon Medical, Inc. (AEMD) | By: Douglas W. House, SA News Editor
The FDA approves Aethlon Medical's (OTCQB:AEMD) Investigational Device Exemption (IDE) supplement allowing the use of Hemopurifier to treat patients infected with the Ebola virus. Under the terms of the approval, the company may treat up to 20 U.S. patients at no more than 10 sites.
The original IDE covered the use of the device in patients infected with the hepatitis C virus.
Previously: Aethlon Medical up on successful Ebola treatment (Nov. 17)
Latest on Aethlon Medical, Inc. (aemd: Get latest price)
Unveiled House Spending Bill Bullish For Ebola Stocks
Wed, Dec 10
Aethlon Medical Inc.: Total Scam Or Legit Company?
Mon, Dec 8
Hydration could save many Ebola victims
Fri, Dec 5
Aethlon ships Hemopurifiers to Nebraska Med Center
Wed, Nov 26
Aethlon Medical continues up move
Mon, Nov 24
SEC suspends trading in certain Ebola-related stocks
Thu, Nov 20
Aethlon Medical up on successful Ebola treatment
Mon, Nov 17
Talent is God-given; be humble.. Fame is man-given; be thankful.. Conceit is self-given; be careful. - John Wooden
